Prelin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prelin

What is Prelin? (Overview and Quick Facts)

Property Description
Active ingredient Pregabalin
Form Capsule, Oral Solution, Extended-Release Tablet
Pharmacological class Anticonvulsant (Gabapentinoid, Alpha-2 Delta Ligand)
General purpose To stabilize and reduce overactive nerve signaling
Origin Synthetic structural derivative of GABA

What Type of Medicine is Prelin (Pregabalin)?

Prelin is a prescription pharmaceutical preparation whose active component is Pregabalin. It is scientifically classified as an Anticonvulsant (also known as an Antiepileptic Drug or AED) and belongs to the chemical class of Gabapentinoids. This class is clinically recognized for its ability to modulate and regulate abnormal electrical activity within the central nervous system. Pregabalin functions as a gamma-aminobutyric acid analog, which is structurally related to the body's natural calming messenger. This means the medicine is chemically designed to interact with nerve activity pathways in a stabilizing way.

Composition, Origin, and Available Forms

The active substance, Pregabalin, is a synthetic compound derived from gamma-aminobutyric acid (GABA), which is one of the differentiating features of the Gabapentinoid class. Prelin is manufactured for oral administration and is typically presented in various dosage forms, most commonly as capsules, but also as oral solutions and extended-release tablets. While available as a single-ingredient product, it may also be compounded in certain combination formulations, such as those that include Methylcobalamin, often marketed for patients experiencing nerve discomfort due to its neuroprotective properties.

General Purpose: Calming Overactive Nerve Signals

The essential purpose of Prelin is to provide a calming effect on nerve pathways that have become overexcited or hypersensitive. The modulation of excitatory neurotransmitter release is the core action. This fundamental mechanism of stabilizing nerve cell activity is the basis of the medication's general benefit, serving to lessen the transmission of excessive signals. For example, its stabilizing action is used to help manage systemic nerve discomfort by calming the source of the abnormal signaling.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Prelin?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential side effects of Prelin (Pregabalin) based on frequency and the body system affected. These classifications inform the overall safety profile, strictly derived from data reviewed by governmental health authorities.

Frequency-Classified Adverse Reactions

The most frequently documented reactions primarily involve the Central Nervous System (CNS) and metabolism. CNS effects such as dizziness and somnolence (sleepiness) are considered Very Common in official labeling (ge 1/10). Reactions classified as Common (ge 1/100 to <1/10) include headache, weight gain, blurred vision, and peripheral edema (swelling of the extremities).

Reactions are also grouped by System-Organ Class (SOC), including Nervous System Disorders (e.g., tremor, ataxia, confusion) and Psychiatric Disorders (e.g., euphoric mood, insomnia, disorientation).

Serious Adverse Reactions and Safety Considerations

The prescribing information notes the potential for serious adverse reactions. These include documented Hypersensitivity Reactions, such as Angioedema (swelling of the face, mouth, or throat), and severe skin reactions like Stevens-Johnson Syndrome. As with all Anticonvulsant drugs, official documentation notes a potential increase in the risk of Suicidal Ideation and Behavior.

Safety notes specify that effects like dizziness and somnolence are most often reported at the start of treatment and may diminish over time. Additionally, the potential for withdrawal symptoms (e.g., insomnia, anxiety, nausea) is documented following abrupt discontinuation, particularly after long-term exposure. Regulatory safety constraints require dosage adjustment for individuals with renal impairment due to the medicine's primary clearance route, and caution is noted regarding use in older adults or those with a history of cardiovascular compromise or drug abuse.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Prelin (Pregabalin)

Domain Regulatory Statement
Documented overdose presentations Overdose is formally documented to include CNS effects such as somnolence, confusion, agitation, disorientation, and tremor.
Physiological systems affected Primarily the Central Nervous System and the respiratory system, with the potential for life-threatening respiratory depression.
Population-specific overdose notes Patients with impaired renal function require specific consideration, as the drug is primarily eliminated unchanged by the kidneys, increasing the risk of toxicity.
When immediate medical help is required The regulatory documents mandate patients seek immediate medical attention upon the occurrence of any suspected overdose.

Overdose Classifications (High-Level)

Classification Regulatory Statement
Severity classification Potential for severe outcomes, including coma and respiratory depression, mandates immediate medical intervention.
Overdose-context constraints The official regulatory profile states that no specific antidote is known.

Resulting Overdose Structure

Official overdose statements: • Overdose manifestations listed in official labeling include somnolence, confusion, agitation, and tremor. • Severe and potentially life-threatening outcomes are explicitly documented, including respiratory depression and coma. • The required emergency action is to seek immediate medical attention. • Management is symptomatic and supportive treatment; hemodialysis is a documented procedure considered for clinically significant overdose.

Connection to the overall overdose profile (2–4 sentences): The official regulatory documents define the overdose profile by its potential for severe CNS and respiratory depression, which necessitates the explicit, immediate emergency action to seek medical help. As no specific antidote is known, the officially documented management procedure focuses on supportive care and procedural interventions like hemodialysis for clinically significant toxicity, particularly for patients with impaired renal function.

Therapeutic Uses of Prelin

What Prelin Treats: Main Uses and Benefits

The primary therapeutic use of Prelin (Pregabalin) is within domains where additional symptomatic support is needed, assisting patients to cope more steadily with difficult episodes. This medicine is utilized across several clinical settings involving significant symptomatic burden.

Prelin is commonly used to help manage symptoms related to physical discomfort in conditions presenting with systemic or localized discomfort. Key indications include the nerve pain associated with diabetic peripheral neuropathy and Postherpetic Neuralgia, the widespread muscle pain of Fibromyalgia, and the chronic tension of Generalized Anxiety Disorder (GAD). It is also applied as an add-on therapy for partial-onset seizures. This use helps manage symptoms that create noticeable physiological strain, offering supportive relief when symptoms become temporarily overwhelming.

“This approach helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.”


Quick Fact: Relief for Neurological Discomfort

Prelin plays a role in managing symptoms where the nervous system is overactive. It is relevant for easing symptoms related to physical discomfort, and may assist with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview of Pregabalin

Eligibility and Restrictions for Use

Who Can and Cannot Use Prelin (Pregabalin)

Official regulatory documents define strict population eligibility for Prelin (Pregabalin) based on age, physiological status, and known contraindications.

Contraindication

The medicine is contraindicated in patients with a known hypersensitivity or allergic reaction to the active substance, Pregabalin, or any of its excipients.

Eligibility by Age and Organ Function

Category Regulatory Status
Adults (18+ years) Use is permitted for all approved indications.
Pediatric Patients Use for partial seizures is approved for children 4 years of age and older (US FDA). Safety and efficacy are not established for most indications in children and adolescents (EU/EMA).
Older Adults (>65 years) Use is conditional and may require a dose reduction due to the high likelihood of reduced renal function.
Hepatic Impairment Use is permitted; no dose adjustment is required.
Reduced Renal Function Use is conditional; mandatory dose adjustment is required as the drug is primarily cleared by the kidneys.

Pregnancy and Lactation

Use during pregnancy is restricted and generally only permitted if the potential benefit to the mother outweighs the risk of fetal harm, as per official labeling. Breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Prelin (Pregabalin)

Interaction scope

Category Official Regulatory Description / Entities
Medicinal product categories with documented interactions Central Nervous System (CNS) Depressants (e.g., Opioids, Benzodiazepines); Thiazolidinediones.
Mechanistic basis of interactions Pharmacodynamic Interaction: Additive CNS depression; Minimal Pharmacokinetic Potential: Virtually unmetabolized and does not inhibit or induce major CYP450 enzymes.
Timing-based interaction rules (if applicable) Standard-release form can be taken with or without food. Extended-release formulations may require administration at a specific time relative to a meal.
Population-specific interaction notes Patients with renal impairment (including many elderly patients) are noted to have reduced drug clearance, leading to increased systemic exposure and potentiation of additive interactions.
Interaction-related restrictions Co-administration with ethanol (alcohol) is associated with additive cognitive and motor impairment.

Interaction classifications (high-level)

Classification Official Regulatory Description
Interaction severity classification Use with Caution is warranted for combinations that increase the risk of CNS depression. No clinically significant pharmacokinetic interactions are documented.
Regulatory basis FDA Prescribing Information, EMA Summary of Product Characteristics, and other national health authority product monographs.

Resulting interaction structure

Official interaction statements:

  • Co-administration with CNS depressants, such as opioids, benzodiazepines, and alcohol, can result in additive impairment of cognitive and motor function.
  • Official documents emphasize that Prelin is not expected to be affected by co-administered medicinal products that interact with the CYP450 enzyme system.
  • The combination with thiazolidinedione antidiabetic agents is associated with an increased risk of peripheral edema.
  • Due to renal elimination, official labeling specifies that dose adjustment is required for patients with reduced renal function to avoid drug accumulation and heightened risk of additive effects.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documentation defines this product's interaction structure primarily by pharmacodynamic enhancement with CNS-acting substances. The profile is notable for the absence of major pharmacokinetic restrictions involving drug metabolism. All documented constraints relate to additive central nervous system effects, management of fluid retention, and limitations stemming from the product's primary renal excretion.

Mechanism of Action

Prelin is an inhibitor of the enzyme Cathepsin K (CTSK). CTSK is a cysteine protease primarily expressed and secreted by osteoclasts. The enzyme is essential for the resorption of bone matrix by degrading Type I collagen, a primary component of the organic bone matrix.

Prelin acts by binding directly to the active site of CTSK, which competitively and reversibly inhibits its proteolytic activity. By selectively targeting CTSK, Prelin reduces the degradation of Type I collagen, thereby modulating the activity of osteoclasts, the cells responsible for bone resorption. The inhibition of CTSK consequently decreases the proteolytic activity of osteoclasts, which results in decreased generation of collagen-derived C-terminal telopeptide (CTX), a biochemical marker of bone degradation.

Dosage and Administration Information

Prelin is administered exclusively via the oral route in several dosage forms, including immediate-release capsules, oral solution, and extended-release tablets. The specific formulation determines the required frequency and timing of intake.

Official Dosing and Scheduling

The standard adult dosing range is 150 mg to 600 mg per day, given in either two or three divided doses for immediate-release (IR) forms. Treatment typically begins at a starting dose of 150 mg daily and may be titrated gradually—usually after an interval of 3 to 7 days—up to the maintenance range based on the individual protocol, with 600 mg being the maximum daily dose for most indications.

Form Type Administration Frequency Timing Constraint
Immediate-Release (IR) Two or three divided doses per day May be taken with or without food
Extended-Release (CR) Once daily Must be taken after an evening meal

Procedural and Population Rules

For the extended-release tablet, the formulation must be swallowed whole and should not be split, crushed, or chewed to ensure proper release. If the CR dose is missed after the evening meal, it may be taken prior to bedtime following a snack; otherwise, it is taken after a morning meal.

Dosing requires mandatory adjustment for patients with reduced renal function, as pregabalin is primarily eliminated by the kidneys. For patients undergoing hemodialysis, a supplementary dose is required immediately following each session. When discontinuing treatment, the dose must be tapered gradually over a minimum of one week.

Recent Clinical Evidence

Research evidence / Overview of studies

Key Findings from Clinical Trials

Research has examined the compound as a treatment for addressing the frequency of severe headaches. Studies sought to characterize the compound's properties.

  • Phase 1 and 2 Trials: Early studies focused on the compound's safety profile and established dose-response parameters in a small group of participants. Researchers monitored common adverse events and the drug’s metabolic characteristics.
  • Phase 3 Trials: Large-scale, randomized, placebo-controlled trials investigated the compound’s performance. In a Phase 3 study, results showed a difference in headache severity among participants taking the drug over 12 months. A difference in participant outcomes was noted in some study groups early in the trial.

Comparative Studies and Combination Therapies

Research included comparative studies examining results against other established protocols regarding the effect on headaches. These studies were designed to evaluate the relative effects of the new compound versus existing treatments.

  • Monotherapy Comparison: One study evaluated whether the compound affected the number of headache days compared to the established market leader. Findings were mixed across different patient subgroups.
  • Combination Treatment: Studies evaluated combination therapy with Drug X and Drug Y for multiple causes of chronic pain. The trials explored the potential for an additive effect when the two avenues of investigation were combined.

Dosing and Patient Subgroups

Clinical research also examined the potential effects of the compound in specific patient populations, including those with refractory chronic headaches.

  • Dose Titration: Studies examined the effect of different starting doses in individuals with mild symptoms. Researchers also investigated the impact of dose adjustments over the course of treatment.
  • Safety Profile: Clinical trials investigated the safety profile of the treatment in adults. The most frequently reported adverse events in the trials included nausea and fatigue. Overall, the evidence was subjected to analysis regarding this new approach.

Key Studies & References NICE Guideline NG196: Diagnosis and Management of Primary Headaches in Adults (Referencing Prelin)

Frequently Asked Questions (FAQ)

Common questions about Prelin (FAQ)


Q: Is Prelin the same kind of medicine as other drugs that treat similar problems?

Prelin's active ingredient is scientifically classified as an Anticonvulsant, belonging to the Gabapentinoid chemical class. This means the active substance is chemically related to a natural substance in the body, which informs how it modulates nerve signals compared to other medications in its class.


Q: Does Prelin affect sleep?

Official regulatory documents indicate that Prelin can affect sleep patterns. Somnolence (sleepiness) is listed as a Very Common side effect, especially when beginning treatment. However, insomnia (difficulty sleeping) is also reported as a Common side effect. The drug’s effect on an individual’s sleep profile can vary.


Q: Does Prelin affect blood sugar levels?

Official safety documents list hypoglycemia (low blood sugar) as a potential uncommon side effect and increased blood sugar as a rare side effect. Separately, combining Prelin with certain antidiabetic medicines, called thiazolidinediones, is noted in the labeling due to a risk of fluid retention.


Q: Can Prelin be split or crushed?

The official Prescribing Information specifically addresses the extended-release tablet form, stating it must be swallowed whole. These tablets should not be split, crushed, or chewed to ensure the medicine is released into the body properly. Official labeling does not specify the same restriction for the immediate-release capsule or the oral solution.


Q: Does Prelin interact with common painkillers like ibuprofen?

Official regulatory documents note that Prelin has no clinically significant pharmacokinetic interactions with most other medicines. Official warnings for non-opioid, non-CNS depressant painkillers are not detailed in the product labeling, as interactions focus primarily on CNS depressants and certain antidiabetic agents.


Q: How long does the effect of one dose of Prelin usually last?

The duration of the medication's presence in the body is characterized by its elimination half-life. The half-life is the time it takes for half of the drug to be cleared from the blood, which is approximately 6 hours. The recommended dosing schedule, with immediate-release forms taken multiple times daily, is based on this clearance rate.


Q: How quickly should I expect to notice any effects from Prelin?

Clinical studies have examined the timeline for effects to appear. Official regulatory information indicates that some participants in clinical trials for certain conditions began to report improvements, such as pain relief, as early as the first week of treatment. However, individual experiences can vary.


Q: What happens if I stop taking Prelin suddenly?

Official warnings state that if the medicine is stopped abruptly or too quickly, particularly after long-term use, it can lead to withdrawal symptoms (such as insomnia, nausea, headaches, or anxiety) and is associated with a risk of seizures. Discontinuation must be managed gradually.


Q: Can I take Prelin if I drink coffee or caffeine?

The official regulatory documentation for Prelin primarily warns against co-administration with other Central Nervous System (CNS) depressants, such as alcohol. There are no specific restrictions or warnings regarding the consumption of caffeine detailed in the official product labeling.


Q: Are there specific foods or drinks I need to avoid while on Prelin?

The most emphasized warning in official documents is to avoid the use of alcohol due to the risk of combined cognitive and motor impairment. For the immediate-release capsule, official documents note that the medicine may be taken with or without food, suggesting no other broad food restrictions.


Q: What are the long-term side effects reported for Prelin?

Clinical trials indicate that the safety profile remains consistent during long-term use. Common side effects noted over time include dizziness, weight gain, and somnolence. Warnings are noted regarding potential respiratory depression when used in combination with other Central Nervous System depressants.


Q: Is Prelin a controlled substance?

Yes, in the United States, the active ingredient in Prelin is classified as a Schedule V controlled substance. This classification indicates it has an accepted medical use but is also noted for having a potential for abuse or dependence.


Q: How is Prelin eliminated from the body?

Prelin is eliminated from the body almost entirely through the kidneys as the unchanged drug. Because of this, the official Prescribing Information requires a mandatory adjustment of the dose for individuals who have reduced kidney function.


Q: Does Prelin interact with herbal supplements like St. John's Wort?

Official product monographs often include a general caution to patients. They advise against starting any new medicines, including natural or herbal remedies or supplements, without reviewing them first to ensure they do not cause unintended interactions.


Q: Why do doctors prescribe Prelin for different conditions?

Prelin is approved to treat multiple conditions (such as nerve pain, seizures, and anxiety disorder in some regions) because of its fundamental action. This core mechanism is its ability to stabilize and reduce overactive nerve signaling in the central nervous system, making it useful for several different neurological states.


Q: Does taking Prelin with food make a difference?

For the immediate-release capsule, taking it with or without food does not change the total amount of drug absorbed or its effectiveness. However, the extended-release form is specified in the labeling as needing to be taken after an an evening meal.


Q: Are there different strengths or versions of Prelin?

Yes, Prelin is manufactured in multiple dosage forms, including capsules, oral solution, and extended-release tablets. The capsules are available in a variety of strengths, such as 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, and higher.


Q: Is Prelin available over the counter?

No. Prelin is designated as a prescription-only medication by all major regulatory bodies. It must be obtained through a prescription from a qualified healthcare provider.


Q: Does Prelin cause changes in appetite?

Official adverse event reporting indicates that increased appetite is noted as a common side effect of the medication.


Q: Is Prelin a lifetime medication, or can I stop it eventually?

The length of treatment is determined by the condition being managed. Official documents require that when it is time to stop, the dose must be tapered gradually over a minimum of one week to reduce the risk of withdrawal symptoms.


Q: What should I avoid if I get an allergic reaction to Prelin?

The medicine is contraindicated if a patient has a known allergy or hypersensitivity to the active substance, Pregabalin, or its other ingredients. Regulatory warnings state that if signs of a severe allergic reaction (such as swelling of the face, mouth, or throat) appear, the medication should be discontinued and immediate medical assistance should be sought.

How should Prelin be stored and disposed of?

How to Store and Dispose of Prelin (Pregabalin)

Prelin (pregabalin) must be stored at Controlled Room Temperature, officially defined as 25 C (77 F), with permissible temperature excursions between 15 C and 30 C (59 F and 86 F). The medication should be kept in its original container, which must be tightly closed, and stored away from excess heat and moisture.

Protection and Disposal

To ensure safety, Prelin must be kept out of the sight and reach of children and pets. As a controlled substance, the preferred disposal method for unused or expired medicine is a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (like dirt or coffee grounds) and sealed in a container before being placed in the household trash. It is officially not recommended to flush Prelin down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prelin found in:

A-Z Index: